Ionis Pharmaceuticals, Inc. IONS 深 沪
等待开盘 11-14 09:30:00 美东时间
29.06
+1.750
+6.41%
华盛通- 最 高29.09
- 今 开27.30
- 成交量 594.51万股
- 最 低 27.25
- 昨 收 27.31
- 总市值 483.98万
- 52周最高 86.74
- 市盈率 静 --
- 换手率 3569.69%
- 52周最低 27.25
- 委 比 -0.74%
- 总股本 0.00亿
- 历史最高 86.74
- 量 比 0.65
- 振 幅 6.74%
- 历史最低 6.25
- 每 手 1
- 风险率 14.46%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Ionis Pharmaceuticals Inc收涨6.41%，成交额1.69亿美元
11月14日，Ionis Pharmaceuticals Inc（IONS）收涨6.41%，报29.06美元，成交额1.69亿美元，市值48.4亿美元。 行情数...
53分钟前
美股大行评级 | 富国银行维持英伟达"超配"评级！但目标价从315美元降至300美元
今日重点评级关注：花旗：维持Faeth Therapeutics"买入"评级，目标价从55美元升至60美元；HC Wainwright & Co.：维持Ocular Therapeutix"买入"评级，目标价从25美元升至28美元
11-11 10:50
Wells Fargo Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $80
Wells Fargo analyst Yanan Zhu maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $95 to $80.
11-10 23:12
Ionis Pharmaceuticals Inc 2026财年第3季度营收2.43亿美元，同比增长54.88%
最新财报显示，Ionis Pharmaceuticals Inc 2026财年第3季度实现： 营业收入：2.43亿美元 同比：增长54.88% 每股收益：-0...
11-10 03:00
Why Is Ionis Pharmaceuticals Stock at a 52-Week Low on Monday?
Ionis Pharmaceuticals Inc. (NASDAQ:IONS) stock is trading at a 52-week low after the company lowered Tryngolza (olezarsen) 2026 product sales guidance. • Ionis Pharmaceuticals shares are approaching critical lows. What’s behind IONS weakness? Tryngolza Guidance Reduction The cholesterol-lowering dru...
11-10 02:33
Ionis Pharmaceuticals Q3 Adj. EPS $(0.40) Beats $(1.21) Estimate, Sales $243.000M Beat $182.117M Estimate
Ionis Pharmaceuticals (NASDAQ:IONS) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(1.21) by 66.94 percent. This is a 34.43 percent increase over losses of $(0.61) per share from the same period last year. The company reported quarterly sales of $243.000...
11-09 20:04
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2026 Financial Results
Praxis Precision Medicines reported FDA reviews of relutrigine (PDUFA target: Dec 27, 2026) and ulixacaltamide HCI (PDUFA target: Jan 29, 2027), with topline results from the EMERALD study for relutrigine in DEEs expected in Q4 2026. Cash and investments of $1.3 billion as of September 2026 provide runway into 2028. The company plans an Investor Day on November 12, 2026, to discuss commercial strategies and pipeline.
11-09 12:00
KKR, Constellation Energy On Deck Monday As Private Credit, Power Face Test
KKR headlines Monday’s reports, with investors weighing whether fundraising momentum can offset a sharp year-to-date stock decline. Constellation Energy, Barrick Mining, Ferguson Enterprises and ORIX report before the open; Occidental Petroleum, JBS, Skydance, Take-Two Interactive Software and Rocke...
11-09 04:31
Ionis Pharmaceuticals Inc收涨1.6%，成交额1.14亿美元
11月7日，Ionis Pharmaceuticals Inc（IONS）收涨1.6%，报39.42美元，成交额1.14亿美元，市值65.51亿美元。 行情数据...
11-07 06:00
Ionis Pharmaceuticals Inc收跌1.96%，成交额6636.64万美元
10月31日，Ionis Pharmaceuticals Inc（IONS）收跌1.96%，报43.52美元，成交额6636.64万美元，市值72.32亿美元...
10-31 04:59
